Strongbridge Biopharma Plc Launches the Uncovering Periodic Paralysis Genetic Testing Program
current pharmaceutical news | September 25, 2017
Strongbridge Biopharma plc, a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced the launch of a genetic testing program for hyperkalemic or hypokalemic periodic paralysis.